Krystal Biotech (NASDAQ:KRYS) Lowered to Hold at Zacks Investment Research

Share on StockTwits

Krystal Biotech (NASDAQ:KRYS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports.

According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “

Several other research analysts have also recently commented on the company. BidaskClub raised Misonix from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 3rd. Cowen reissued a “buy” rating and set a $6.50 target price on shares of Daseke in a research note on Monday, May 6th. Chardan Capital set a $20.00 target price on La Jolla Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, June 24th. HC Wainwright set a $126.00 target price on AnaptysBio and gave the stock a “buy” rating in a research note on Monday, June 24th. Finally, Guggenheim reaffirmed a “buy” rating and set a $100.00 price target (down from $105.00) on shares of World Wrestling Entertainment in a report on Tuesday, June 25th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $58.60.

KRYS traded down $0.03 on Wednesday, hitting $48.17. 3,119 shares of the company were exchanged, compared to its average volume of 275,036. Krystal Biotech has a twelve month low of $14.30 and a twelve month high of $51.67. The stock has a market capitalization of $816.51 million, a P/E ratio of -50.23 and a beta of 0.98. The company has a current ratio of 33.28, a quick ratio of 33.28 and a debt-to-equity ratio of 0.03. The business has a 50-day moving average price of $39.64.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Tuesday, May 7th. The company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. Research analysts forecast that Krystal Biotech will post -1.45 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Strs Ohio purchased a new stake in Krystal Biotech during the 2nd quarter worth about $92,000. Knott David M lifted its holdings in Krystal Biotech by 145.4% during the 1st quarter. Knott David M now owns 3,686 shares of the company’s stock worth $121,000 after buying an additional 2,184 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in Krystal Biotech during the 4th quarter worth about $159,000. Citigroup Inc. purchased a new stake in shares of Krystal Biotech in the 4th quarter valued at about $214,000. Finally, TD Asset Management Inc. purchased a new stake in shares of Krystal Biotech in the 1st quarter valued at about $268,000. 39.52% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.

Featured Story: How do CD ladders protect against rising interest rates?

Get a free copy of the Zacks research report on Krystal Biotech (KRYS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.